Powered by

First Asian patient has been included in the global Phase III program for PledOx(R) and will trigger a milestone payment of 600 MJPY (c.49 MSEK) to PledPharma

Jan 10, 2019 - Thomson Reuters ONE

Stockholm, January 10, 2019. PledPharma AB (publ) and Solasia Pharma K.K. announces that the first patient has been included in the global Phase III program for the drug candidate PledOx(R) in Japan. This constitutes an important milestone for both companies. The inclusion will trigger a payment from PledPharma's partner Solasia Pharma of 600 MJPY, equivalent to approximately 49 MSEK.

The global Phase III program for PledOx(R) consists of two double-blind, randomized, placebo-controlled st...